



**Externally-Led Patient-Focused Drug Development Meeting
July 22, 2022**

Adrenoleukodystrophy (ALD) in Adulthood

- 10:00-10:05 AM **Welcome Remarks**
Kathleen O’Sullivan-Fortin
Symptomatic woman with ALD, ALD Connect Board Member
- 10:05-10:15 AM **FDA Introduction to PFDD**
Wilson Bryan, MD
Director, Office of Tissues and Advanced Therapies, FDA
- 10:15-10:30 AM **Clinical Features of ALD and AMN & Therapeutic Approaches**
Florian Eichler, MD
Associate Professor of Neurology at Harvard Medical School, ALD Connect Board Member
- 10:30-10:35 AM **Meeting Overview and Introduction**
James Valentine, JD, MHS
Meeting Moderator
- 10:35-10:40 AM **Demographic Polling**
James Valentine, JD, MHS
Meeting Moderator
- Topic 1: Living with ALD: Men with adrenomyeloneuropathy, cerebral ALD, symptomatic women with ALD**
- 10:40-11:05 AM **Pre-recorded Panelists**
- 11:05-12:30 PM **Polling and Audience Discussion**
- Zoom Discussion Starters (live)
 - Patient/caregiver audience remote polling
 - Moderated audience discussion (telephone and written comments)
- 12:30-1:00 PM **Break**

continued on page 2...



Topic 2: Approaches to Treatments for ALD and AMN: Men with adrenomyeloneuropathy, cerebral ALD, symptomatic women with ALD

- | | |
|--------------|---|
| 1:00-1:25 PM | Pre-recorded Panelists |
| 1:25-2:40 PM | Polling and Audience Discussion <ul style="list-style-type: none">• Zoom Discussion Starters (live)• Patient/caregiver audience remote polling• Moderated audience discussion (telephone and written comments) |
| 2:40-2:50 PM | Meeting Summary
<i>Larry Bauer, RN MA</i> |
| 2:50-2:55 PM | Concluding Remarks & Next Steps
<i>Kathleen O’Sullivan-Fortin</i>
<i>Symptomatic woman with ALD, ALD Connect Board Member</i> |